New strategies to tackle diabetic kidney disease

Duygu Batu Demir, Mark E. Cooper

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Purpose of review: The purpose of this review is to provide an overview of recent preclinical and clinical studies, which demonstrate new insights for the treatment of diabetic kidney disease (DKD) and to outline future directions with respect to novel therapies. 

Recent findings: Positive findings with respect to new glucose-lowering agents such as sodium-dependent glucose transporter 2 inhibitors may lead to a change in the way we treat diabetic individuals with or at risk of DKD. Additional positive phase 2 clinical studies with drugs that have hemodynamic actions such as endothelin antagonists and mineralocorticoid receptor antagonists have led to larger phase 3 trials with atrasentan and finerenone, respectively, in order to address if these drugs indeed delay the development of end-stage renal disease. A number of other pathways are currently under active preclinical investigation and hopefully over the next decade will lead to promising drug candidates for subsequent clinical trials. 

Summary: DKD remains an area of active preclinical and clinical investigation. Positive results with some of the more promising agents should lead to strategies to reverse, attenuate or prevent DKD.

Original languageEnglish
Pages (from-to)348-354
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume25
Issue number4
DOIs
Publication statusPublished - 1 Jul 2016

Keywords

  • albuminuria
  • diabetes
  • end-stage renal disease
  • nephropathy
  • sodium-dependent glucose transporter 2

Cite this

@article{576da7fbc6d848b49fad99e16da11067,
title = "New strategies to tackle diabetic kidney disease",
abstract = "Purpose of review: The purpose of this review is to provide an overview of recent preclinical and clinical studies, which demonstrate new insights for the treatment of diabetic kidney disease (DKD) and to outline future directions with respect to novel therapies. Recent findings: Positive findings with respect to new glucose-lowering agents such as sodium-dependent glucose transporter 2 inhibitors may lead to a change in the way we treat diabetic individuals with or at risk of DKD. Additional positive phase 2 clinical studies with drugs that have hemodynamic actions such as endothelin antagonists and mineralocorticoid receptor antagonists have led to larger phase 3 trials with atrasentan and finerenone, respectively, in order to address if these drugs indeed delay the development of end-stage renal disease. A number of other pathways are currently under active preclinical investigation and hopefully over the next decade will lead to promising drug candidates for subsequent clinical trials. Summary: DKD remains an area of active preclinical and clinical investigation. Positive results with some of the more promising agents should lead to strategies to reverse, attenuate or prevent DKD.",
keywords = "albuminuria, diabetes, end-stage renal disease, nephropathy, sodium-dependent glucose transporter 2",
author = "Demir, {Duygu Batu} and Cooper, {Mark E.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/MNH.0000000000000234",
language = "English",
volume = "25",
pages = "348--354",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

New strategies to tackle diabetic kidney disease. / Demir, Duygu Batu; Cooper, Mark E.

In: Current Opinion in Nephrology and Hypertension, Vol. 25, No. 4, 01.07.2016, p. 348-354.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - New strategies to tackle diabetic kidney disease

AU - Demir, Duygu Batu

AU - Cooper, Mark E.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose of review: The purpose of this review is to provide an overview of recent preclinical and clinical studies, which demonstrate new insights for the treatment of diabetic kidney disease (DKD) and to outline future directions with respect to novel therapies. Recent findings: Positive findings with respect to new glucose-lowering agents such as sodium-dependent glucose transporter 2 inhibitors may lead to a change in the way we treat diabetic individuals with or at risk of DKD. Additional positive phase 2 clinical studies with drugs that have hemodynamic actions such as endothelin antagonists and mineralocorticoid receptor antagonists have led to larger phase 3 trials with atrasentan and finerenone, respectively, in order to address if these drugs indeed delay the development of end-stage renal disease. A number of other pathways are currently under active preclinical investigation and hopefully over the next decade will lead to promising drug candidates for subsequent clinical trials. Summary: DKD remains an area of active preclinical and clinical investigation. Positive results with some of the more promising agents should lead to strategies to reverse, attenuate or prevent DKD.

AB - Purpose of review: The purpose of this review is to provide an overview of recent preclinical and clinical studies, which demonstrate new insights for the treatment of diabetic kidney disease (DKD) and to outline future directions with respect to novel therapies. Recent findings: Positive findings with respect to new glucose-lowering agents such as sodium-dependent glucose transporter 2 inhibitors may lead to a change in the way we treat diabetic individuals with or at risk of DKD. Additional positive phase 2 clinical studies with drugs that have hemodynamic actions such as endothelin antagonists and mineralocorticoid receptor antagonists have led to larger phase 3 trials with atrasentan and finerenone, respectively, in order to address if these drugs indeed delay the development of end-stage renal disease. A number of other pathways are currently under active preclinical investigation and hopefully over the next decade will lead to promising drug candidates for subsequent clinical trials. Summary: DKD remains an area of active preclinical and clinical investigation. Positive results with some of the more promising agents should lead to strategies to reverse, attenuate or prevent DKD.

KW - albuminuria

KW - diabetes

KW - end-stage renal disease

KW - nephropathy

KW - sodium-dependent glucose transporter 2

UR - http://www.scopus.com/inward/record.url?scp=84965006501&partnerID=8YFLogxK

U2 - 10.1097/MNH.0000000000000234

DO - 10.1097/MNH.0000000000000234

M3 - Review Article

VL - 25

SP - 348

EP - 354

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -